We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The drugs will be available to any eligible patients three months after NICE publishes its final guidance. Midostaurin and brentuximab vedotin will be available at a confidential discounted price. Read More
In a 17-0 vote, the FDA’s Antimicrobial Drugs Advisory Committee voted that the data show a favorable risk-benefit profile for TPOXX (tecovirimat) for its proposed indication for treating smallpox caused by variola virus in adults and pediatric patients. Read More
The CHMP also recommended approval of Carmustine Obvius (carmustine) a generic drug for treatment Hodgkin’s disease, non-Hodgkin’s lymphoma and brain tumors. Read More
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended three medicines for approval and eight extensions at its April 23-26 meeting. Read More